Lotus Eye Hospital and Institute Ltd
Fundamental Score
Lotus Eye Hospital and Institute Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of LOTUSEYE across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (20.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Conservative Debt Levels (D/E: 0.08)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
12 factors identified
Below-Average Return on Equity (1.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.99%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 320.93x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Limited Growth History (4.09% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-12.83% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-12.83% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Lotus Eye Hospital and Institute Ltd
About LOTUSEYE
Business Overview
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.
Company Details
Key Leadership
Corporate Events
LOTUSEYE Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Lotus Eye Hospital and Institute Ltd (LOTUSEYE)?
As of 11 Feb 2026, 10:16 am IST, Lotus Eye Hospital and Institute Ltd (LOTUSEYE) is currently trading at ₹122.83. The stock has a market capitalization of ₹215.03 (Cr).
Is LOTUSEYE share price Overvalued or Undervalued?
LOTUSEYE is currently trading at a P/E ratio of 320.93x, compared to the industry average of 52.84x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Lotus Eye Hospital and Institute Ltd share price?
Key factors influencing LOTUSEYE's price include its quarterly earnings growth (Sales Growth: 1.01%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Lotus Eye Hospital and Institute Ltd a good stock for long-term investment?
Lotus Eye Hospital and Institute Ltd shows a 5-year Profit Growth of -12.83% and an ROE of 1.22%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.08 before investing.
How does Lotus Eye Hospital and Institute Ltd compare with its industry peers?
Lotus Eye Hospital and Institute Ltd competes with major peers in the Hospital. Investors should compare LOTUSEYE's P/E of 320.93x and ROE of 1.22% against the industry averages to determine its competitive standing.
What is the P/E ratio of LOTUSEYE and what does it mean?
LOTUSEYE has a P/E ratio of 320.93x compared to the industry average of 52.84x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹321 for every ₹1 of annual earnings.
How is LOTUSEYE performing according to Bull Run's analysis?
LOTUSEYE has a Bull Run fundamental score of 22/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does LOTUSEYE belong to?
LOTUSEYE operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Lotus Eye Hospital and Institute Ltd.
What is Return on Equity (ROE) and why is it important for LOTUSEYE?
LOTUSEYE has an ROE of 1.22%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Lotus Eye Hospital and Institute Ltd generates profits from shareholders' equity.
How is LOTUSEYE's debt-to-equity ratio and what does it indicate?
LOTUSEYE has a debt-to-equity ratio of 0.08, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is LOTUSEYE's dividend yield and is it a good dividend stock?
LOTUSEYE offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has LOTUSEYE grown over the past 5 years?
LOTUSEYE has achieved 5-year growth rates of: Sales Growth 4.09%, Profit Growth -12.83%, and EPS Growth -12.83%.
What is the promoter holding in LOTUSEYE and why does it matter?
Promoters hold 40.64% of LOTUSEYE shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is LOTUSEYE's market capitalization category?
LOTUSEYE has a market capitalization of ₹215 crores, placing it in the Small-cap category.
How volatile is LOTUSEYE stock?
LOTUSEYE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for LOTUSEYE?
LOTUSEYE has a 52-week high of ₹N/A and low of ₹N/A.
What is LOTUSEYE's operating profit margin trend?
LOTUSEYE has a 5-year average Operating Profit Margin (OPM) of 12.69%, indicating the company's operational efficiency.
How is LOTUSEYE's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 1.01% and YoY Profit Growth of 20.00%.
What is the institutional holding pattern in LOTUSEYE?
LOTUSEYE has FII holding of 0.00% and DII holding of 0.02%. Significant institutional holding often suggests professional confidence in the stock.